4
Changes in Ownership
ARROWHEAD PHARMACEUTICALS, INC. Filed Acc 0001209191-22-009052
Chief Executive Officer sold 146,388 shares at an average $51.91 ($7,598,864)
- Chief Executive Officer acquired 146,388 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Anzalone Christopher Richard Chief Executive Officer | 2022-02-11 | Option exercise | +146,388 | $5.19 | $759,754 | 4,204,022 | D |
| Anzalone Christopher Richard Chief Executive Officer | 2022-02-11 | Sale | −40,853 | $53.11 | $2,169,703 | 4,163,169 | D |
| Anzalone Christopher Richard Chief Executive Officer | 2022-02-11 | Sale | −42,153 | $52.28 | $2,203,759 | 4,121,016 | D |
| Anzalone Christopher Richard Chief Executive Officer | 2022-02-11 | Sale | −61,482 | $50.90 | $3,129,434 | 4,059,534 | D |
| Anzalone Christopher Richard Chief Executive Officer | 2022-02-11 | Sale | −1,900 | $50.51 | $95,969 | 4,057,634 | D |
| Derivatives | |||||||
| Anzalone Christopher Richard Chief Executive Officer | 2022-02-11 | Option exercise · Stock Option (right to buy Common Stock) | −146,388 | 615,033 | D | ||
| Open-market sales · 146,388 sh · avg $51.91 · $7,598,864 | |||||||
Loading xslF345X03/doc4.xml…